The South African Hypertension Guideline 2006 is evidence-based but not cost-effective

South African Medical Journal

Volumn 96, Issue 11, 2006, Pages 1170-1173

  Gaziano, Thomas A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEVINOLIN;

ACCURACY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; HYPERTENSION; LIFESTYLE; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SOUTH AFRICA; SYSTOLIC BLOOD PRESSURE; TREATMENT PLANNING;

ADULT; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COMORBIDITY; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRACTICE GUIDELINES; RISK FACTORS; SOUTH AFRICA;

EID: 33751369700     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Gaziano T, Reddy, KS, Paccaud, F, Horton, S. Cardiovascular Disease. In: Jamison D, et al., eds. Disease Control Priorities in Developing Countries, 2nd ed. New York: Oxford University Press and The World Bank, 2006; 645-662.
2. Bradshaw D, Nannan N, Laubscher K, et al. South African National Burden of Disease Study 2000: Estimates of Provincial Mortality. Cape Town: Medical Research Council, 2004.
3. Pestana JA, Steyn K, Leiman A, Hartzenberg GM. The direct and indirect costs of cardiovascular disease in South Africa in 1991. S Afr Med J 1996; 86: 679-684.
4. World Bank. World Development Indicators. Washington, DC: The World Bank, 2002.
5. American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. Dallas, Texas; American Heart Association, 2003.
6. Joint National Hypertension Guideline Working Group 2006. South African Hypertension Guideline 2006. S Afr Med J 2006; 96(4, Part 2); 337-362.
7. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.[see comment]. Lancet 2004; 364: 937-952.
8. Rodgers A, Lawes C., Gaziano T, Vos T. The growing burden of risk from high blood pressure, cholesterol, and bodyweight. In: Jamison D, ed. Disease Control Priorities in Developing Countries. New York: Oxford University Press and the World Bank, 2006.
9. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. Cost-effectiveness analysis in heart disease, Part II; Preventive therapies. Prog Cardiovasc Dis 1995; 37: 243-271.
10. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
11. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344: 3-10.
12. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997; 157: 657-667.
13. Writing Group of the PREMIER Collaborative Research Group. Effects of Comprehensive Lifestyle Modification on Blood Pressure Control: Main Results of the PREMIER Clinical Trial. JAMA 2003; 289: 2083-2093.
14. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individuals absolute cardiovascular risk. [see comment]. Lancet 2005; 365: 434-441.
15. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139-185.
16. Diagnosis, management and prevention of the common dyslipidaemias in South Africa - clinical guideline, 2000. South African Medical Association and Lipid and Atherosclerosis Society of Southern Africa Working Group. S Afr Med J 2000; 90(2, Part 2); 164-174, 176-178.
17. Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH. Cost-effectiveness analysis of hypertension guidelines in South Africa: Absolute risk versus blood pressure level. Circulation 2005; 112: 3569-3576.
18. Manuel DG, Lim J, Tanuseputro P, et al. Revisiting Rose: strategies for reducing coronary heart disease. BMJ 2006; 332: 659-662.